Balyasny Asset Management’s Moderna MRNA Stock Holding History

Balyasny Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$264K	Sell	5,191 -8,599	-62%	-$401K	﹤0.01%	2611
2025 Q4	$407K	Sell	13,790 -613,695	-98%	-$16.7M	﹤0.01%	2611
2025 Q3	$16.2M	Buy	+627,485	New	+$17.5M	0.02%	809
2024 Q4	–	Sell	-13,574	Closed	-$649K	–	3077
2024 Q3	$907K	Sell	13,574 -26,802	-66%	-$2.46M	﹤0.01%	2012
2024 Q2	$4.79M	Buy	40,376 +30,076	+292%	+$3.81M	0.01%	1190
2024 Q1	$1.1M	Buy	+10,300	New	+$1.04M	﹤0.01%	1744
2023 Q4	–	Sell	-700,341	Closed	-$72.3M	–	2747
2023 Q3	$72.3M	Buy	700,341 +386,625	+123%	+$43.1M	0.15%	179
2023 Q2	$38.1M	Buy	313,716 +308,504	+5,919%	+$41.2M	0.08%	322
2023 Q1	$800K	Sell	5,212 -149,900	-97%	-$24.7M	﹤0.01%	1816
2022 Q4	$27.9M	Buy	+155,112	New	+$25.4M	0.08%	346
2022 Q3	–	Sell	-37,377	Closed	-$5.67M	–	3115
2022 Q2	$5.34M	Buy	+37,377	New	+$5.34M	0.02%	902
2022 Q1	–	Sell	-66,529	Closed	-$11.2M	–	2702
2021 Q4	$16.9M	Buy	+66,529	New	+$19.5M	0.06%	479
2020 Q3	–	Sell	-481,631	Closed	-$30.9M	–	1479
2020 Q2	$30.9M	Buy	+481,631	New	+$26.4M	0.27%	90
2019 Q4	–	Sell	-11,557	Closed	-$184K	–	1364
2019 Q3	$184K	Sell	11,557 -37,420	-76%	-$553K	﹤0.01%	1083
2019 Q2	$717K	Buy	+48,977	New	+$1.05M	﹤0.01%	1154

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balyasny Asset Management's MRNA Position: Q1 2026 in Review

Balyasny Asset Management reduced its Moderna (MRNA) stake by 62% in Q1 2026, selling an estimated $401K and leaving 5,191 shares worth $264K. The position accounts for ﹤0.01% of the portfolio, ranked #2611.

Balyasny Asset Management first reported a position in MRNA in Q2 2019 and has held it in 15 quarters since. The position peaked at $72.3M in Q3 2023. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

Balyasny Asset Management held 5,191 shares of Moderna worth $264K as of Q1 2026.
Balyasny Asset Management sold 8,599 Moderna shares in Q1 2026, an estimated $401K.
Moderna made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2611 holding.
Balyasny Asset Management first reported a position in Moderna in Q2 2019 and has held it in 15 quarters since.
Balyasny Asset Management's Moderna position peaked at $72.3M in Q3 2023.
722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.